Plasma 24S hydroxycholesterol response to statins in Alzheimer's disease patients: Effects of gender, CYP46, and ApoE polymorphisms

Journal of Molecular Neuroscience

Volumn 33, Issue 1, 2007, Pages 51-55

  Vega, Gloria Lena ^a,b   Weiner, Myron F ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cholesterol metabolism; Hydroxycholesterol

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL 24 HYDROXYLASE; CHOLESTEROL DERIVATIVE; CHOLESTEROL ESTER TRANSFER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; MEMBRANE LIPID; MEVINOLIN; NICOTINIC ACID; OXYGENASE; OXYSTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CATALYSIS; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER; NERVE CELL NECROSIS; NONHUMAN; REVIEW; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; CHOLESTEROL; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS; STEROID HYDROXYLASES;

EID: 35348837212     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-007-0040-5     Document Type: Review

References (23)

1. Bjorkhem, I., Lutjohann, D., Breuer, O., Sakinis, A., & Wennmalm, A. (1997). Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24 (S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. Journal of Biological Chemistry, 272, 30178-30184.
2. Bjorkhem, I., Lutjohann, D., Diczfalusy, U., Stahle, L., Ahlborg, G., & Wahren, J. (1998). Cholesterol homeostasis in human brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. Journal of Lipid Research, 39, 1594-1600.
3. Dietschy, J. M., & Turley, S. D. (2004). Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. Journal of Lipid Research, 45, 1375-1397.
4. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 5856-5861.
5. Friedhoff, L. T., Cullen, E. I., Geoghagen, N. S., & Buxbaum, J. D. (2001). Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. International Journal of Neuropsychopharmacology, 4, 127-130.
6. Ingelsson, M., Jesneck, J., Irizarry, M. C., Hyman, B. T., & Rebeck, G. W. (2004). Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. Neuroscience Letters, 367, 228-231.
7. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., & Drachman, D. A. (2000). Statins and the risk of dementia. Lancet, 356, 1627-1631.
8. Lennernas, H., & Fager, G. (1997). Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clinical Pharmacokinetics, 32, 403-425.
9. Lutjohann, D., Papassotiropoulos, A., Bjorkhem, I., Locatelli, S., Bagli, M., Oehring, R. D., et al. (2000). Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. Journal of Lipid Research, 41, 195-198.
10. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
11. Morell, P., Quarles, R. H., & Norton, W. T. (1994). Myelin formation, structure and biochemistry. In R. W. Siegel, R. W. Alber, & P. B. Mollinoff (Eds.), Basic neurochemistry: Molecular, cellular and medical aspects (pp. 117-143). New York: Raven.
12. Papassotiropoulos, A., Lutjohann, D., Bagli, M., Locatelli, S., Jessen, F., Rao, M. L., et al. (2000). Plasma 24S-hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport, 11, 1959-1962.
13. Papassotiropoulos, A., Streffer, J. R., Tsolaki, M., Schmid, S., Thal, D., Nicosia, F., et al. (2003). Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Archives of Neurology, 60, 29-35.
14. Saheki, A., Terasaki, T., Tamai, I., & Tsuji A. (1994). In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmaceutical Research, 11, 305-311.
15. Shah, S. N., & Johnson, R. C. (1988). Effect of serum lipoproteins on growth and sterol synthesis in cultured rat brain glial cells. Journal of Neurochemistry, 50, 1529-1536.
16. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., & Simons, K. (1998). Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America, 95, 6460-6464.
17. Simons, M., Schwarzler, F., Lutjohann, D., von Bergmann, K., Beyreuther, K., Dichgans, J., et al. (2002). Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Annals of Neurology, 52, 346-350.
18. Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., et al. (2005). Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Archives of Neurology, 62, 753-757.
19. Vega, G. L., Weiner, M., Kolsch, H., von Bergmann, K., Heun, R., Lutjohan, D., et al. (2004). The effects of gender and CYP46 and apo E polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients treated with statins. Current Alzheimer Research, 1, 71-77.
20. Vega, G. L., Weiner, M. F., Lipton, A. M., Von Bergmann, K., Lutjohann, D., Moore, C., et al. (2003). Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Archives of Neurology, 60, 510-515.
21. Walsh, D. M., & Selkoe, D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 44, 181-193.
22. Weiner, M. F., Vega, G., Risser, R. C., Honig, L. S., Cullum, C. M., Crumpacker, D., et al. (1999). Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. Biological Psychiatry, 45, 633-638.
23. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., & Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology, 57, 1439-1443.